文献速递血脂与心血管预防心律失常

PCSK9与HMG-CoA还原酶抑制的孟德尔随机化研究:认知功能影响

Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

本研究利用约74万欧洲裔参与者的全基因组关联数据,通过药物靶点孟德尔随机化评估长期PCSK9抑制和他汀类(HMGCR抑制)对神经认知结局的影响。结果显示遗传代理的PCSK9抑制对认知表现、记忆及皮质表面积无显著影响;而HMGCR抑制与认知表现下降、反应时间延长及皮质表面积减小存在不良关联,但未影响阿尔茨海默病或路易体痴呆生物标志物。

要点

  • 遗传代理的PCSK9抑制未显示对认知功能或痴呆风险的不良影响。
  • HMGCR抑制与认知表现下降、反应时间延长及皮质表面积减小相关。
  • HMGCR抑制未影响阿尔茨海默病进展或路易体痴呆风险的生物标志物。

核心结论

  • 遗传证据未发现PCSK9抑制相关的不良认知影响,提示中性认知特征。
  • HMGCR抑制观察到不良神经认知效应,可能被他汀类的心血管获益所抵消,但仍需药物警戒。

研究设计与样本

  • 药物靶点孟德尔随机化研究,利用 predominantly 欧洲 ancestry 的 GWAS 汇总数据。
  • 从 HMGCR 和 PCSK9 基因提取单核苷酸多态性,以低密度脂蛋白胆固醇为工具。
  • 合并样本约74万参与者,评估多种认知和痴呆结局。

主要发现

  • PCSK9抑制对认知表现、记忆表现或皮质表面积无显著影响。
  • HMGCR抑制与认知表现下降相关(beta: -0.082; 95% CI: -0.16 to -0.0080; P = 0.03)。
  • HMGCR抑制与反应时间延长相关(beta = 0.00064; 95% CI: 0.00030-0.00098; P = 0.0002)。
  • HMGCR抑制与皮质表面积减小相关(beta = -0.18; 95% CI: -0.35 to -0.014; P = 0.03)。
  • PCSK9和HMGCR抑制均未影响阿尔茨海默病进展或路易体痴呆风险的生物标志物。

临床怎么用

  • 对于关注认知安全性的患者,PCSK9抑制未显示遗传证据支持的不良认知效应。
  • 使用他汀类药物时,应关注认知相关不良反应,但需权衡其明确的心血管获益。

局限性

  • 研究基于欧洲 ancestry 人群的遗传数据,外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lipid-lowering therapy with statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition are effective strategies in reducing cardiovascular disease risk; however, concerns remain about potential long-term adverse neurocognitive effects. OBJECTIVES: This genetics-based study aimed to evaluate the relationships of long-term PCSK9 inhibition and statin use on neurocognitive outcomes. METHODS: We extracted single-nucleotide polymorphisms in 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and PCSK9 from predominantly European ancestry-based genome-wide association studies summary-level statistics of low-density lipoprotein cholesterol and performed drug-target Mendelian randomization, proxying the potential neurocognitive impact of drug-based PCSK9 and HMGCR inhibition using a range of outcomes to capture the complex facets of cognition and dementia. RESULTS: Using data from a combined sample of ∼740,000 participants, we observed a neutral cognitive profile related to genetic PCSK9 inhibition, with no significant effects on cognitive performance, memory performance, or cortical surface area. Conversely, we observed several adverse associations for HMGCR inhibition with lowered cognitive performance (beta: -0.082; 95% CI: -0.16 to -0.0080; P = 0.03), reaction time (beta = 0.00064; 95% CI: 0.00030-0.00098; P = 0.0002), and cortical surface area (beta = -0.18; 95% CI: -0.35 to -0.014; P = 0.03). Neither PCSK9 nor HMGCR inhibition impacted biomarkers of Alzheimer's disease progression or Lewy body dementia risk. Consistency of findings across Mendelian randomization methods accommodating different assumptions about genetic pleiotropy strengthens causal inference. CONCLUSIONS: Using a wide range of cognitive function and dementia endpoints, we failed to find genetic evidence of an adverse PCSK9-related impact, suggesting a neutral cognitive profile. In contrast, we observed adverse neurocognitive effects related to HMGCR inhibition, which may well be outweighed by the cardiovascular benefits of statin use, but nonetheless may warrant pharmacovigilance.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Rosoff DB, Bell AS, Jung J, et al. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function. J Am Coll Cardiol. 2022. PMID: 35953131. doi:10.1016/j.jacc.2022.05.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。